Comprehensive Asthma Management: Guidelines for Clinicians

References

• National Heart, Lung, and Blood Institute. Asthma Management and Prevention. A Practical Guide for Public Health Officials and Health Care Professionals. Publication No. 96–3659A, National Institutes of Health, Bethesda, MD 1995
   Google Scholar
• National Asthma Education and Prevention Program. Guidelines for the Diagnosis and Management of Asthma. Expert Panel Report 2. National Institutes of Health, Bethesda, MD 1997
   Google Scholar
• National Asthma Education Program. Guidelines for the Diagnosis and Management of Asthma. Publication No. 91–3042, National Institutes of Health, Bethesda, MD 1991
   Google Scholar
• Sly R M. Changing asthma mortality and sales of inhaled bronchodilators and antiasthmatic drugs. Ann Allergy 1994; 73: 439–443
   PubMedGoogle Scholar
• Sly R M. Changing asthma mortality. Ann Allergy 1994; 73: 259–268
   PubMedGoogle Scholar
• Beasley R, Burgess C, Crane J, et al. Pathology of asthma and its clinical implications. J Allergy Clin Immunol 1993; 92: 148–154
   PubMed Web of Science ®Google Scholar
• Howarth P H, Bradding P, Quint D, et al. Cytokines and airway inflammation. Ann N Y Acad Sci 1994; 725: 69–82
   PubMedGoogle Scholar
• Cockroft D W. Airway hyperresponsiveness: therapeutic implications. Ann Allergy 1987; 59: 405–414
   PubMedGoogle Scholar
• Gleich G J, Flavahan N A, Fujisawa T, et al. The eosinophil as a mediator of damage to respiratory epithelium: a model for bronchial hyperreactivity. J Allergy Clin Immunol 1988; 51: 776–781
   Google Scholar
• Hogg J C. Pathology of asthma. J Allergy Clin Immunol 1993; 92: 1–5
   PubMed Web of Science ®Google Scholar
• Larsen G L. The late asthmatic response. Chest 1988; 93: 1287–1289
   PubMed Web of Science ®Google Scholar
• O'Byrne P M, Dolovich J, Hargreave F E. Late asthmatic responses. Am Rev Respir Dis 1987; 136: 740–751
   PubMed Web of Science ®Google Scholar
• De Monchy J G, Kauffman H F, Venge P, et al. Bronchoalveolar eosinophilia during allergen‐induced late asthmatic reactions. Am Rev Respir Dis 1985; 131: 373–376
   PubMed Web of Science ®Google Scholar
• Kemp J P. Approaches to asthma management. Realities and recommendations. Arch Intern Med 1993; 153: 805–812
   PubMedGoogle Scholar
• Beasley R, Roche W R, Roberts J A, et al. Cellular events in the bronchi in mild asthma and after bronchial provocation. Am Rev Respir Dis 1989; 139: 806–817
   PubMed Web of Science ®Google Scholar
• Israel E, Cohn J, Dube L, et al. Effect of treatment with zileuton, a 5‐lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. JAMA 1996; 275: 931–936
   PubMed Web of Science ®Google Scholar
• Adachi J D. Corticosteroid‐induced osteoporosis. Am J Med Sci 1997; 313: 41–49
   PubMedGoogle Scholar
• Adachi J D, Bensen W G, Bianchi F, et al. Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year follow‐up. J Rheumatol 1996; 23: 995–1000
   PubMed Web of Science ®Google Scholar
• Djukanovic R, Wilson J W, Britten K M, et al. Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am Rev Respir Dis 1992; 145: 669–674
   PubMed Web of Science ®Google Scholar
• Hanania N A, Chapman K R, Kesten S. Adverse effects of inhaled corticosteroids. Am J Med 1995; 98: 196–208
   PubMed Web of Science ®Google Scholar
• Potential adverse endocrine effects of inhaled corticosteroids. J Paed Child Health 1996; 32: 278–280
   PubMedGoogle Scholar
• Toogood J H, Baskerville J C, Markov A E, et al. Bone mineral density and the risk of fracture in patients receiving long‐term inhaled steroid therapy for asthma. J Allergy Clin Immunol 1995; 96: 157–166
   PubMedGoogle Scholar
• Hoag J E, McFadden E R, Jr. Long‐term effect of cromolyn sodium on nonspecific bronchial responsiveness: a review. Ann Allergy 1991; 66: 53–63
   PubMedGoogle Scholar
• Ullman A, Svedmyr N. Salmeterol, a new long acting inhaled β2‐adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients. Thorax 1988; 43: 674–678
   PubMed Web of Science ®Google Scholar
• Johnson M. Salmeterol: a novel drug for the treatment of asthma. Agents Actions Suppl 1991; 34: 79–95
   PubMedGoogle Scholar
• Kemp J P, Dockhorn R J, Busse W W, et al. Prolonged effect of inhaled salmeterol against exercise‐induced bronchospasm. Am J Respir Crit Care Med 1994; 150: 1612–1615
   PubMed Web of Science ®Google Scholar
• Greening A P, Ind P W, Northfield M, et al. Added salmeterol versus higher‐dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994; 344: 219–224
   PubMed Web of Science ®Google Scholar
• Ramsdale E H, Otis J, Kline P A, et al. Prolonged protection against methacholine‐induced bronchoconstriction by the inhaled β2‐agonist formoterol. Am Rev Respir Dis 1989; 143: 998–1001
   Google Scholar
• Rabe K F, Jorres R, Nowak D, et al. Comparison of the effects of salmeterol and formoterol on airway tone and responsiveness over 24 hours in bronchial asthma. Am Rev Respir Dis 1993; 147: 1436–1441
   PubMed Web of Science ®Google Scholar
• Becker A B, Simons F ER. Formoterol, a new long acting selective β2‐adrenergic receptor agonist: double‐blind comparison with salbutamol and placebo in children with asthma. J Allergy Clin Immunol 1989; 84: 891–895
   PubMedGoogle Scholar
• Yates D H, Sussman H S, Shaw M J, et al. Regular formoterol treatment in mild asthma. Effect on bronchial responsiveness during and after treatment. Am J Respir Crit Care Med 1995; 152: 1170–1174
   PubMed Web of Science ®Google Scholar
• Finnerty I P, Lee C, Wilson S, et al. Effects of theophylline on inflammatory cells and cytokines in asthmatic subjects: a placebo‐controlled parallel group study. Eur Respir J 1996; 9: 1672–1677
   PubMed Web of Science ®Google Scholar
• Djukanovic R, Finnerty J P, Lee C, et al. The effects of theophylline on mucosal inflammation in asthmatic airways: biopsy results. Eur Respir J 1995; 8: 831–833
   PubMedGoogle Scholar
• Banner K H, Page C P. Theophylline and selective phosphodiesterase inhibitors as anti‐inflammatory drugs in the treatment of bronchial asthma. Eur Respir J 1995; 8: 996–1000
   PubMed Web of Science ®Google Scholar
• Sullivan P, Bekir S, Jaffar Z, et al. Anti‐inflammatory effects of low‐dose oral theophylline in atopic asthma. Lancet 1994; 343: 1006–1008
   PubMedGoogle Scholar
• Torphy T J, Undem B J. Phosphodiesterase inhibitors: new opportunities for the treatment of asthma. Thorax 1991; 46: 512–523
   PubMed Web of Science ®Google Scholar
• McFadden E R, Jr, Gilbert I A. Exercise‐induced asthma. N Engl J Med 1994; 330: 1362–1367
   PubMed Web of Science ®Google Scholar
• Bone R C. Goals of asthma management. A step‐care approach. Chest 1996; 109: 1056–1065
   PubMedGoogle Scholar
• Nimmagadda S R, Spahn J D, Leung D Y, Szefler S J. Steroid‐resistant asthma: evaluation and management. Ann Allergy Asthma Immunol 1996; 77: 345–355
   PubMed Web of Science ®Google Scholar
• Sher E R, Leung D Y, Surs W, et al. Steroid‐resistant asthma. Cellular mechanisms contributing to inadequate response to glucocorticoid therapy. J Clin Invest 1994; 93: 33–39
   PubMed Web of Science ®Google Scholar
• Bryant D H, Rogers P. Effects of ipratropium bromide nebulizer solution with and without preservatives in the treatment of acute and stable asthma. Chest 1992; 102: 742–747
   PubMedGoogle Scholar
• Rebuck A S, Chapman K R, Abboud R, et al. Nebulized anticholinergic and sympathomimetic treatment of asthma and chronic obstructive airways disease in the emergency room. Am J Med 1987; 82: 59–64
   PubMed Web of Science ®Google Scholar
• Morrison J F, Pearson S B, Dean H G. Parasympathetic nervous system in nocturnal asthma. Br Med J 1988; 296: 1427–1429
   PubMed Web of Science ®Google Scholar
• Gross N J. Ipratropium bromide. N Engl J Med 1988; 319: 486–494
   PubMed Web of Science ®Google Scholar
• Evans R E, III. Environmental control and immunotherapy for allergic disease. J Allergy Clin Immunol 1992; 90: 462–468
   PubMed Web of Science ®Google Scholar
• Kotses H, Lewis P, Creer T L. Environmental control of asthma self‐management. J Asthma 1990; 27: 375–384
   PubMed Web of Science ®Google Scholar
• Boulet L P, Giguere M C, Milot J, et al. Effects of long‐term use of high‐dose inhaled steroids on bone density and calcium metabolism. J Allergy Clin Immunol 1994; 94: 796–803
   PubMed Web of Science ®Google Scholar
• Meeran K, Hattersley A, Burrin J, et al. Oral and inhaled corticosteroids reduce bone formation as shown by plasma osteocalcin levels. Am J Respir Crit Care Med 1995; 153: 333–336
   Google Scholar
• Chervinsky P, van As A, Bronsky E A, et al. Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma. J Allergy Clin Immunol 1994; 94: 676–683
   PubMed Web of Science ®Google Scholar
• Noonan M, Chervinsky P, Busse W W, et al. Fluticasone propionate reduces oral prednisone use while it improves asthma control and quality of life. Am J Respir Crit Care Med 1995; 152: 1467–1473
   PubMed Web of Science ®Google Scholar
• Booth H, Richmond I, Ward C, et al. Effect of high dose inhaled fluticasone propionate on airway inflammation in asthma. Am J Respir Crit Care Med 1995; 152: 45–52
   PubMed Web of Science ®Google Scholar
• Bootsma G P, Dekhuijzen P NR, Festen J, et al. Fluticasone propionate does not influence bone metabolism in contrast to beclomethasone dipropionate. Am J Respir Crit Care Med 1996; 253: 924–930
   Google Scholar
• Gauvreau G M, Doctor J, Watson R M, et al. Effects of inhaled budesonide on allergen‐induced airways responses and airway inflammation. Am J Respir Crit Care Med 1996; 154: 1267–1271
   PubMed Web of Science ®Google Scholar
• Clark D J, Clark R A, Lipworth B J. Adrenal suppression with inhaled budesonide and fluticasone propionate given by large volume spacer to asthmatic children. Thorax 1996; 51: 941–943
   PubMed Web of Science ®Google Scholar
• Clark D J, Grove A, Cargill R I, Lipworth B J. Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients. Thorax 1996; 51: 262–266
   PubMed Web of Science ®Google Scholar
• Samuelsson B, Dahlen S E, Lindgren J A, et al. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 1987; 237: 1171–1176
   PubMed Web of Science ®Google Scholar
• Abramovitz M, Wong E, Cox M E, et al. 5‐Lipoxygenase‐activating protein stimulates the utilization of arachidonic acid by 5‐lipoxygenase. Eur J Biochem 1993; 215: 105–111
   PubMedGoogle Scholar
• Barnes N C, Piper P J, Costello J F. Comparative effects of inhaled leukotriene C4 leukotriene D4 and histamine in normal human subjects. Thorax 1984; 39: 500–504
   PubMed Web of Science ®Google Scholar
• Laitinen L, Laitinen A, Haahtela T, et al. Leukotriene E4 and granulocytic infiltration into asthmatic airways. Lancet 1993; 341: 989–990
   PubMed Web of Science ®Google Scholar
• Palmer R M, Stepney R J, Higgs G A, et al. Chemokinetic activities of arachidonic and lipoxygenase products on leukocytes of different species. Prostaglandins 1980; 20: 411–418
   PubMed Web of Science ®Google Scholar
• Hoover R L, Karnovsky M J, Austen K F, et al. Leukotriene B4 action on endothelium mediates augmented neutrophil/endothelial adhesion. Proc Natl Acad Sci USA 1984; 81: 2191–2193
   PubMed Web of Science ®Google Scholar
• Martin T R, Pistorese B P, Chi E Y, et al. Effects of leukotriene B4 in the human lung. Recruitment of neutrophils into the alveolar spaces without a change in protein permeability. J Clin Invest 1989; 84: 1609–1619
   PubMed Web of Science ®Google Scholar
• Smith L J, Glass M G, Minkwitz M C. Inhibition of leukotriene D4‐induced bronchoconstriction in subjects with asthma. A concentration‐effect study of ICI‐204,219. Clin Pharmacol Ther 1993; 54: 430–436
   PubMed Web of Science ®Google Scholar
• Botto A, DeLepeleire I, Rochette F, et al. MK‐0476 causes prolonged, potent, LTD4 receptor antagonism in the airways of asthmatics. Am J Respir Crit Care Med 1994; 149: A465
   Google Scholar
• Finnerty J P, Wood‐Baker R, Thomson H, Holgate S T. Role of leukotrienes in exercise‐induced asthma. Inhibitory effect of ICI 204219, a potent leukotriene D4 receptor antagonist. Am Rev Respir Dis 1992; 245: 746–749
   Google Scholar
• Reiss T F, Bronsky E, Hendeles L, et al. MK‐0476, a potent leukotriene (LTD4) antagonist, inhibits exercise induced bronchoconstriction in asthmatics at the end of a once daily dosing schedule. Am J Respir Crit Care Med 1995; 252: A377
   Google Scholar
• Findlay S R, Barden J M, Easley C B, Glass M. Effect of the oral leukotriene antagonist, ICI 204,219, on antigen‐induced bronchoconstriction in subjects with asthma. J Allergy Clin Immunol 1992; 89: 1040–1045
   PubMed Web of Science ®Google Scholar
• Taniguchi Y, Tamura G, Honma M, et al. The effect of an oral leukotriene antagonist, ONO‐1078, on allergen‐induced immediate bronchoconstriction in asthmatic subjects. J Allergy Clin Immunol 1993; 92: 507–512
   PubMed Web of Science ®Google Scholar
• Reiss T F, Altman L C, Chervinsky P, et al. Effects of montelukast (MK‐0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma. J Allergy Clin Immunol 1996; 98: 528–534
   PubMed Web of Science ®Google Scholar
• Reiss T F. Montelukast, a cys LT1‐receptor antagonist, improves signs and symptoms of asthma with a dose as low as 10 mg once daily
   Google Scholar
• Spector S L, Smith L J, Glass M. Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. Am J Respir Crit Care Med 1994; 150: 618–623
   PubMed Web of Science ®Google Scholar
• Gaddy J N, Margolskee D J, Bush R K, et al. Bronchodilation with a potent and selective leukotriene D4 (LTD4) receptor antagonist (MK‐571) in patients with asthma. Am Rev Respir Dis 1992; 146: 358–363
   PubMedGoogle Scholar
• Dahlén B, Margolskee D J, Zetterstrom O, et al. Effect of the leukotriene receptor antagonist MK‐0679 on baseline pulmonary function in aspirin sensitive asthmatic subjects. Thorax 1993; 48: 1205–1210
   PubMed Web of Science ®Google Scholar
• Diamant Z, Timmers M C, van der Veen H, et al. The effect of MK‐0591, a novel 5‐lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen‐induced airway responses in asthmatic subjects in vivo. J Allergy Clin Immunol 1995; 95: 42–51
   PubMed Web of Science ®Google Scholar
• Friedman B S, Bel E H, Buntinx A, et al. Oral leukotriene inhibitor (MK‐886) blocks allergen‐induced airway responses. Am Rev Respir Dis 1993; 247: 839–844
   Google Scholar
• Storms W, Friedman B S, Zhang J, et al. Treating asthma by blocking the lipoxygenase pathway. Am J Respir Cell Mol Biol 1995; 151: A377
   Google Scholar
• Robinson D S, Hamid Q, Ying S, et al. Predominant TH2‐like bronchoalveolar T‐lymphocyte population in atopic asthma. N Engl J Med 1992; 326: 298–304
   PubMed Web of Science ®Google Scholar
• Van Oosterhout A J, Ladenius A R, Savelkoul H F, et al. Effect of anti‐IL‐5 and IL‐5 on airway hyperreactivity and eosinophils in guinea pigs. Am Rev Respir Dis 1993; 247: 548–552
   Google Scholar
• Milne A A, Piper P J. Effects of interleukin‐5 inhibition on antigen‐induced airway hyperresponsiveness and cell accumulation in guinea pigs. Ann N Y Acad Sci 1994; 725: 282–287
   PubMedGoogle Scholar
• Weller P F, Rand T H, Goelz S E, et al. Human eosinophil adherence to vascular endothelium mediated by binding to vascular cell adhesion molecule 1 and endothelial leukocyte adhesion molecule 1. Proc Natl Acad Sci USA 1991; 88: 7430–7433
   PubMed Web of Science ®Google Scholar
• Abraham W M, Sielczak M W, Ahmed A, et al. a4‐Integrins mediate antigen‐induced late bronchial responses and prolonged airway hyperresponsiveness in sheep. J Clin Invest 1994; 93: 776–787
   PubMed Web of Science ®Google Scholar
• Barnes P J, Chung K F, Page C P. Platelet‐activating factor as a mediator of allergic disease. J Allergy Clin Immunol 1988; 81: 919–934
   PubMed Web of Science ®Google Scholar
• Barnes N C. New developments in the treatment of asthma and chronic obstructive pulmonary disease. Respir Med 1993; 87(Suppl B)53–56
   PubMedGoogle Scholar
• Cheung D, Timmers M C, Zwinderman A H, et al. Neutral endopeptidase activity and airway hyperresponsiveness to neurokinin A in asthmatic subjects in vivo. Am Rev Respir Dis 1993; 248: 1467–1473
   Google Scholar
• Ichinose M, Nakajima N, Takahashi T, et al. Protection against bradykinin‐induced bronchoconstriction in asthmatic patients by neurokinin receptor antagonist. Lancet 1992; 340: 1248–1251
   PubMed Web of Science ®Google Scholar
• Kelly S J, Uri A J, Freeland H S, et al. Effects of colchicine on IgE‐mediated early and late airway reactions. Chest 1995; 207: 985–991
   Google Scholar
• Virchow J C, Jr, Kroegel C, Matthys H. Antiasthma drug delivery. What is on the horizon?. Clin Pharmacokinet 1994; 27: 85–93
   PubMedGoogle Scholar
• DeBlaquiere P, Christensen D B, Carter W B, Martin T R. Use and misuse of metered‐dose inhalers by patients with chronic lung disease. Am Rev Respir Dis 1989; 140: 910–916
   PubMedGoogle Scholar
• Rand C S, Wise R A. Measuring adherence to asthma medication regimens. Am J Respir Crit Care Med 1994; 149: S69–S76
   PubMed Web of Science ®Google Scholar
• Newnham D M, Lipworth B J. Nebulizer performance, pharmacokinetics, airways and systemic effects of salbutamol given via a novel nebulizer delivery system (“Ventstream”). Thorax 1994; 49: 762–770
   PubMed Web of Science ®Google Scholar